Инжект

For the treatment of iron-deficiency anaemia in patients undergoing chronic haemodialysis and who are receiving supplemental erythropoietin therapy

Изграждане на сондажно-изливни пилоти за дълбоко фундиране и укрепване

ПОЛИМЕРИНЖЕКТ ЕООД е частно строително дружество, което работи основно в сектора на специалното, хидротехническото, тунелното строителство и минната индустрия. Фирмата използва технологии с анкерни системи, пилотни конструкции, шпунтови стени, циментови и полимерни състави. Специализирани сме в извършване на укрепителни мероприятия на база анкерни системи в комбинация с пръскани бетони, изпълнение на микропилоти, берлински и шпунтови стени.

Ние особено много държим на стриктното спазване на поетите ангажименти, а целта ни е, чрез изключителен професионализъм в областта, в която работим, дисциплина и организираност на персонала, своевременно да отговорим на предизвикателствата на новото време.Ежедневно се стремим към подобрения и усъвършенстване, което е видно от многобройните ни успешно завършени проекти и вярваме, че и занапред ще продължим да поддържаме линията на висок професионализъм и сигурност при реализиране на инженерните предизвикателства.

Меню

* Линейка инъекционных материалов «Инжект» прошла «Экспертную комиссию по инновационным технологиям и техническим решениям» и включена в Реестр № 4/2013, и Реестр № 1/2016 от 29.02.2016 г. инновационных технологий и технических решений, применяемых в строительстве на объектах городского заказа города Москвы.

© 2017 ООО «Инжект». Все права защищены.

Инжект

Ferinject 50 mg iron/mL dispersion for injection/infusion.

2. Qualitative and quantitative composition

One mL of dispersion contains ferric carboxymaltose corresponding to 50 mg iron.

Each 2 mL vial contains ferric carboxymaltose corresponding to 100 mg iron.

Each 10 mL vial contains ferric carboxymaltose corresponding to 500 mg iron.

Each 20 mL vial contains ferric carboxymaltose corresponding to 1,000 mg iron.

Excipient(s) with known effect

One mL of dispersion contains up to 5.5 mg (0.24 mmol) sodium, see section 4.4.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Dispersion for injection/infusion. Dark brown, non-transparent, aqueous solution.

4. Clinical particulars
4.1 Therapeutic indications

Ferinject is indicated for the treatment of iron deficiency when (see section 5.1):

– oral iron preparations are ineffective.

– oral iron preparations cannot be used.

– there is a clinical need to deliver iron rapidly.

The diagnosis of iron deficiency must be based on laboratory tests.

4.2 Posology and method of administration

Monitor carefully patients for signs and symptoms of hypersensitivity reactions during and following each administration of Ferinject.

Ferinject should only be administered when staff trained to evaluate and manage anaphylactic reactions is immediately available, in an environment where full resuscitation facilities can be assured. The patient should be observed for adverse effects for at least 30 minutes following each Ferinject administration (see section 4.4).

The posology of Ferinject follows a stepwise approach:

[1] determination of the individual iron need,

[2] calculation and administration of the iron dose(s), and

[3] post-iron repletion assessments.

These steps are outlined below:

Step 1: Determination of the iron need

The individual iron need for repletion using Ferinject is determined based on the patient’s body weight and haemoglobin (Hb) level. Refer to Table 1 for determination of the total iron need. 2 doses may be required to replenish the total iron need, see Step 2 for the maximum individual iron doses.

Iron deficiency must be confirmed by laboratory tests as stated in section 4.1.

Table 1: Determination of the total iron need

Patient body weight

below 35 kg

70 kg and above

30 mg/kg body weight

15 mg/kg body weight

15 mg/kg body weight

Step 2: Calculation and administration of the maximum individual iron dose(s)

Based on the total iron need determined, the appropriate dose(s) of Ferinject should be administered taking into consideration the following:

Adults and adolescents aged 14 years and older

A single Ferinject administration should not exceed:

• 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)

• 1,000 mg of iron (20 mL Ferinject)

The maximum recommended cumulative dose of Ferinject is 1,000 mg of iron (20 mL Ferinject) per week. If the total iron need is higher, then the administration of an additional dose should be a minimum of 7 days apart from the first dose.

Children and adolescents aged 1 to 13 years

A single Ferinject administration should not exceed:

• 15 mg iron/kg body weight

• 750 mg of iron (15 mL Ferinject)

The maximum recommended cumulative dose of Ferinject is 750 mg of iron (15 mL Ferinject) per week. If the total iron need is higher, then the administration of an additional dose should be a minimum of 7 days apart from the first dose.

Step 3: Post-iron repletion assessments

Re-assessment should be performed by the clinician based on the individual patient’s condition. The Hb level should be re-assessed no earlier than 4 weeks post final Ferinject administration to allow adequate time for erythropoiesis and iron utilisation. In the event the patient requires further iron repletion, the iron need should be recalculated (see Step 1).

Children below 1 year of age

The efficacy and safety of Ferinject has not been investigated in children below 1 year of age. Ferinject is therefore not recommended for use in children in this age group.

Patients with haemodialysis-dependent chronic kidney disease

In adults and adolescents aged 14 years and older, a single maximum daily dose of 200 mg iron should not be exceeded in haemodialysis-dependent chronic kidney disease patients (see also section 4.4).

In children aged 1 to 13 years with chronic kidney disease requiring haemodialysis, the efficacy and safety of Ferinject has not been investigated. Ferinject is therefore not recommended for use in children aged 1 to 13 years with chronic kidney disease requiring haemodialysis.

Method of administration

Ferinject must only be administered by the intravenous route:

• by injection, or

• during a haemodialysis session undiluted directly into the venous limb of the dialyser.

Ferinject must not be administered by the subcutaneous or intramuscular route.

Intravenous injection

Ferinject may be administered by intravenous injection using undiluted dispersion. In adults and adolescents aged 14 years and older, the maximum single dose is 15 mg iron/kg body weight but should not exceed 1,000 mg of iron. In children aged 1 to 13 years, the maximum single dose is 15 mg iron/kg body weight but should not exceed 750 mg of iron. The administration rates are as shown in Table 2:

Table 2: Administration rates for intravenous injection of Ferinject

Volume of Ferinject required

Equivalent iron dose

Administration rate / Minimum administration time

No minimal prescribed time

100 mg iron / min

Intravenous infusion

Ferinject may be administered by intravenous infusion, in which case it must be diluted. In adults and adolescents aged 14 years and older, the maximum single dose is 20 mg iron/kg body weight but should not exceed 1,000 mg of iron. In children aged 1 to 13 years, the maximum single dose is 15 mg iron/kg body weight but should not exceed 750 mg of iron.

For infusion, Ferinject must only be diluted in sterile 0.9% m/V sodium chloride solution as shown in Table 3. Note: for stability reasons, Ferinject should not be diluted to concentrations less than 2 mg iron/mL (not including the volume of the ferric carboxymaltose dispersion). For further instructions on dilution of the medicinal product before administration, see section 6.6.

Table 3: Dilution plan of Ferinject for intravenous infusion

Volume of Ferinject required

Equivalent iron dose

Maximum amount of sterile 0.9% m/V sodium chloride solution

Minimum administration time

No minimal prescribed time

4.3 Contraindications

The use of Ferinject is contraindicated in cases of:

• hypersensitivity to the active substance, to Ferinject or any of its excipients listed in section 6.1.

• known serious hypersensitivity to other parenteral iron products.

• anaemia not attributed to iron deficiency, e.g. other microcytic anaemia.

• evidence of iron overload or disturbances in the utilisation of iron.

4.4 Special warnings and precautions for use

Hypersensitivity reactions

Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes. There have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8).

The risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.

There is also an increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis).

Ferinject should only be administered when staff trained to evaluate and manage anaphylactic reactions are immediately available, in an environment where full resuscitation facilities can be assured. Each patient should be observed for adverse effects for at least 30 minutes following each Ferinject administration. If hypersensitivity reactions or signs of intolerance occur during administration, the treatment must be stopped immediately. Facilities for cardio respiratory resuscitation and equipment for handling acute anaphylactic reactions should be available, including an injectable 1:1000 adrenaline solution. Additional treatment with antihistamines and/or corticosteroids should be given as appropriate.

Hypophosphataemic osteomalacia

Symptomatic hypophosphataemia leading to osteomalacia and fractures requiring clinical intervention including surgery has been reported in the post marketing setting. Patients should be asked to seek medical advice if they experience worsening fatigue with myalgias or bone pain. Serum phosphate should be monitored in patients who receive multiple administrations at higher doses or long-term treatment, and those with existing risk factors for hypophosphataemia. In case of persisting hypophosphataemia, treatment with ferric carboxymaltose should be re-evaluated.

Hepatic or renal impairment

In patients with liver dysfunction, parenteral iron should only be administered after careful benefit/risk assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload.

No safety data on haemodialysis-dependent chronic kidney disease patients receiving single doses of more than 200 mg iron are available.

Parenteral iron must be used with caution in case of acute or chronic infection, asthma, eczema or atopic allergies. It is recommended that the treatment with Ferinject is stopped in patients with ongoing bacteraemia. Therefore, in patients with chronic infection a benefit/risk evaluation has to be performed, taking into account the suppression of erythropoiesis.

Extravasation

Caution should be exercised to avoid paravenous leakage when administering Ferinject. Paravenous leakage of Ferinject at the administration site may lead to irritation of the skin and potentially long lasting brown discolouration at the site of administration. In case of paravenous leakage, the administration of Ferinject must be stopped immediately.

Ferinject contains up to 5.5 mg (0.24 mmol) sodium per mL of undiluted dispersion, equivalent to 0.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 Interaction with other medicinal products and other forms of interaction

The absorption of oral iron is reduced when administered concomitantly with parenteral iron preparations. Therefore, if required, oral iron therapy should not be started for at least 5 days after the last administration of Ferinject.

4.6 Fertility, pregnancy and lactation

There are limited data from the use of Ferinject in pregnant women (see section 5.1). A careful benefit/risk evaluation is required before use during pregnancy and Ferinject should not be used during pregnancy unless clearly necessary.

Iron deficiency occurring in the first trimester of pregnancy can in many cases be treated with oral iron. Treatment with Ferinject should be confined to the second and third trimester if the benefit is judged to outweigh the potential risk for both the mother and the foetus.

Foetal bradycardia may occur following administration of parenteral irons. It is usually transient and a consequence of a hypersensitivity reaction in the mother. The unborn baby should be carefully monitored during intravenous administration of parenteral irons to pregnant women.

Animal data suggest that iron released from Ferinject can cross the placental barrier and that its use during pregnancy may influence skeletal development in the fetus (see section 5.3).

Breast-feeding

Clinical studies showed that transfer of iron from Ferinject to human milk was negligible (≤ 1%). Based on limited data on breast-feeding women it is unlikely that Ferinject represents a risk to the breast-fed child.

There are no data on the effect of Ferinject on human fertility. Fertility was unaffected following Ferinject treatment in animal studies (see section 5.3).

4.7 Effects on ability to drive and use machines

Ferinject is unlikely to impair the ability to drive and use machines.

4.8 Undesirable effects

Table 4 presents the adverse drug reactions (ADRs) reported during clinical studies in which >9,000 subjects (including >100 children and adolescents aged 1 to 17 years) received Ferinject, as well as those reported from the post-marketing experience (see table footnotes for details).

The most commonly reported ADR is nausea (occurring in 3.2% of the subjects), followed by injection/infusion site reactions, hypophosphataemia, headache, flushing, dizziness and hypertension. Injection/infusion site reactions comprise several ADRs which individually are either uncommon or rare.

The most serious ADR is anaphylactic reactions (rare); fatalities have been reported. See section 4.4 for further details.

Table 4: Adverse drug reactions observed during clinical trials and post-marketing experience

System Organ Class

Uncommon (≥ 1/1,000 to

Frequency not known (1)

Immune system disorders

Metabolism and nutritional disorders

Nervous system disorders

Loss of consciousness (1)

Psychiatric disorders

Cardiac disorders

Kounis syndrome (1)

Vascular disorders

Presyncope (2) , syncope (2) , phlebitis

Respiratory, thoracic and mediastinal disorders

Gastrointestinal disorders

Abdominal pain, vomiting, constipation, diarrhoea, dyspepsia

Skin and subcutaneous tissue disorders

Rash (3) , pruritus, urticaria, erythema

Angioedema (2), distant skin discolouration (2) , pallor (2)

Musculoskeletal and connective tissue disorders

Arthralgia, myalgia, pain in extremity, back pain, muscle spasms

Hypophosphataemic osteomalacia (1)

General disorders and administration site conditions

Injection/infusion site reactions (4)

Pyrexia, fatigue, chills, chest pain, oedema peripheral, malaise

Influenza like illness (whose onset may vary from a few hours to several days) (2)

Investigations

Alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased

1 ADRs exclusively reported in the post-marketing setting; estimated as rare.

2 ADRs reported in the post-marketing setting which are also observed in the clinical setting.

3 Includes the following preferred terms: rash (individual ADR determined to be uncommon) and rash erythematous, -generalised, -macular, -maculo-papular, -pruritic (all individual ADRs determined to be rare).

4 Includes, but is not limited to, the following preferred terms: injection/infusion site -pain, -haematoma, -discolouration, -extravasation, -irritation, -reaction, (all individual ADRs determined to be uncommon) and -paraesthesia (individual ADR determined to be rare).

Paediatric population

The safety profile for children and adolescents aged 1 to 17 years is comparable with that of adults. 110 paediatric patients received Ferinject in 7 clinical studies. No serious ADRs were reported. The reported non-serious ADRs were hypophosphataemia (n = 5), urticaria (n = 5), injection/infusion site reactions (n = 4), abdominal pain (n = 2), flushing (n = 2), headache (n = 2), pyrexia (n = 2), liver enzymes increased (n = 2) and rash (n = 2). Constipation, gastritis, hypertension, pruritus and thirst were reported only once.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Yellow Card Scheme

Website: https://yellowcard.mhra.gov.uk/information or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Administration of Ferinject in quantities exceeding the amount needed to correct iron deficit at the time of administration may lead to accumulation of iron in storage sites eventually leading to haemosiderosis. Monitoring of iron parameters such as serum ferritin and transferrin saturation (TSAT) may assist in recognising iron accumulation. If iron accumulation has occurred, treat according to standard medical practice, e.g. consider the use of an iron chelator.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Iron trivalent, parenteral preparation, ATC code: B03AC

Ferinject dispersion for injection/infusion is a colloidal solution of the iron complex ferric carboxymaltose.

The complex is designed to provide, in a controlled way, utilisable iron for the iron transport and storage proteins in the body (transferrin and ferritin, respectively).

Red cell utilisation of 59 Fe from radio-labelled Ferinject ranged from 91% to 99% in subjects with iron deficiency (ID) and 61% to 84% in subjects with renal anaemia at 24 days post-dose.

Ferinject treatment results in an increase in reticulocyte count, serum ferritin levels and TSAT levels to within normal ranges.

Clinical efficacy and safety

The efficacy and safety of Ferinject has been studied in different therapeutic areas necessitating intravenous iron to correct iron deficiency. The main studies are described in more detail below.

Cardiology

Chronic heart failure

Study CONFIRM-HF was a double-blind, randomised, 2-arm study comparing Ferinject (n=150) vs. placebo (n=151) in subjects with chronic heart failure and ID for a treatment period of 52 weeks. At Day 1 and Week 6 (correction phase), subjects received either Ferinject according to a simplified dosing grid using baseline Hb and body weight at screening (see section 4.2), placebo or no dose. At Weeks 12, 24, and 36 (maintenance phase) subjects received Ferinject (500 mg iron) or placebo if serum ferritin was

Study EFFECT-HF was an open-label (with blinded endpoint evaluation), randomised, 2-arm study comparing Ferinject (n=86) vs. standard of care (n=86) in subjects with chronic heart failure and ID for a treatment period of 24 weeks. At Day 1 and Week 6 (correction phase), subjects received either Ferinject according to a simplified dosing grid using baseline Hb and body weight at screening (see section 4.2) or standard of care. At Week 12, (maintenance phase) subjects received Ferinject (500 mg iron) or standard of care if serum ferritin 2 from baseline to Week 24 (LS Mean 1.04 ± 0.44, p=0.02).

Nephrology

Haemodialysis-dependent chronic kidney disease

Study VIT-IV-CL-015 was an open-label, randomised parallel group study comparing Ferinject (n=97) to iron sucrose (n=86) in subjects with ID anaemia undergoing haemodialysis. Subjects received Ferinject or iron sucrose 2– 3 times per week in single doses of 200 mg iron directly into the dialyser until the individually calculated cumulative iron dose was reached (mean cumulative dose of iron as Ferinject: 1,700 mg). The primary efficacy endpoint was the percentage of subjects reaching an increase in Hb of ≥ 1.0 g/dL at 4 weeks after baseline. At 4 weeks after baseline, 44.1% responded to treatment with Ferinject (i.e. Hb increase of ≥ 1.0 g/dL) compared to 35.3% for iron sucrose (p=0.2254).

Non—dialysis-dependent chronic kidney disease

Gastroenterology

Inflammatory bowel disease

Study VIT-IV-CL-008 was a randomised, open-label study which compared the efficacy of Ferinject vs. oral ferrous sulphate in reducing ID anaemia in subjects with inflammatory bowel disease (IBD). Subjects received either Ferinject (n=111) in single doses of up to 1,000 mg iron once per week until the individually calculated iron dose (per Ganzoni formula) was reached (mean cumulative iron dose: 1,490 mg), or 100 mg iron BID as ferrous sulphate (n=49) for 12 weeks. Subjects receiving Ferinject showed a mean increase in Hb from baseline to Week 12 of 3.83 g/dL, which was non-inferior to 12 weeks of twice daily therapy with ferrous sulphate (3.75 g/dL, p=0.8016).

Study FER-IBD-07-COR was a randomised, open-label study comparing the efficacy of Ferinject vs. iron sucrose in subjects with remitting or mild IBD. Subjects receiving Ferinject were dosed according to a simplified dosing grid using baseline Hb and body weight (see section 4.2) in single doses up to 1,000 mg iron, whereas subjects receiving iron sucrose were dosed according to individually calculated iron doses using the Ganzoni formula in doses of 200 mg iron until the cumulative iron dose was reached. Subjects were followed-up for 12 weeks. 65.8% of subjects receiving Ferinject (n=240; mean cumulative iron dose: 1,414 mg) vs. 53.6% receiving iron sucrose (n=235; mean cumulative dose 1,207 mg; p=0.004) had responded at Week 12 (defined as Hb increase ≥ 2 g/dL). 83.8% of Ferinject-treated subjects vs. 75.9% of iron sucrose-treated subjects achieved a Hb increase ≥ 2 g/dL or had Hb within normal limits at Week 12 (p=0.019).

Women’s health

Post partum

Study VIT-IV-CL-009 was a randomised open-label non-inferiority study comparing the efficacy of Ferinject (n=227) vs. ferrous sulphate (n=117) in women suffering from post-partum anaemia. Subjects received either Ferinject in single doses of up to 1,000 mg iron until their individually calculated cumulative iron dose (per Ganzoni formula) was reached, or 100 mg of iron as oral ferrous sulphate BID for 12 weeks. Subjects were followed-up for 12 weeks. The mean change in Hb from baseline to Week 12 was 3.37 g/dL in the Ferinject group (n=179; mean cumulative iron dose: 1,347 mg) vs. 3.29 g/dL in the ferrous sulphate group (n=89), showing non-inferiority between the treatments.

Intravenous iron medicines should not be used during pregnancy unless clearly necessary. Treatment with Ferinject should be confined to the second and third trimester if the benefit is judged to outweigh the potential risk for both the mother and the foetus, see section 4.6.

Limited safety data in pregnant women are available from study FER-ASAP-2009-01, a randomised, open-label, study comparing Ferinject (n=121) vs. oral ferrous sulphate (n=115) in pregnant women in the second and third trimester with ID anaemia for a treatment period of 12 weeks. Subjects received Ferinject in cumulative doses of 1,000 mg or 1,500 mg of iron (mean cumulative dose: 1,029 mg iron) based on Hb and body weight at screening, or 100 mg of oral iron BID for 12 weeks. The incidence of treatment related adverse events was similar between Ferinject treated women and those treated with oral iron (11.4% Ferinject group; 15.3% oral iron group). The most commonly reported treatment-related adverse events were nausea, upper abdominal pain and headache. Newborn Apgar scores as well as newborn iron parameters were similar between treatment groups.

Paediatric population

Adolescents aged 14 years or older were included in 4 studies performed in adults. In addition, paediatric studies were performed in children and adolescents aged 1 to 17 years with iron deficiency anaemia. The most common aetiologies for iron deficiency anaemia were gastrointestinal diseases (e.g. inflammatory bowel disease, Helicobacter pylori gastritis, coeliacic disease) and heavy uterine bleeding.

In a prospective pharmacokinetic/pharmacodynamic phase 2 study (1VIT13036), 35 children at a median age of 9.8 years (range: 1.5-17.5 years) were treated in 2 consecutive dose cohorts with single doses of Ferinject 7.5 mg iron/kg body weight (n = 16) or Ferinject 15 mg iron/kg body weight (n = 19), at a maximum dose of 750 mg iron. Hb, ferritin and TSAT increased dose-dependently. On day 35 after injection, the mean (SD) increase in Hb was 1.9 (1.38) g/dL with Ferinject 7.5 mg iron/kg and 2.8 (1.15) g/dL with Ferinject 15 mg iron/kg. See also section 4.8.

In a prospective, open-label, parallel-group phase 3 study (1VIT17044), efficacy and safety of Ferinject were compared with oral iron therapy. 40 children at a median age of 14.5 years (range:1 to 17 years) were treated with 2 doses of Ferinject 15 mg iron/kg body weight at a 7-day interval (maximum single dose 750 mg) and 39 children at a median age of 14.0 years (range: 1 to 17 years) with oral ferrous sulphate for 28 days. A similar increase in Hb was observed after both treatment with Ferinject and treatment with oral iron sulphate. The increase in Hb from baseline to day 35 (LS Mean [95%CI]) was 2.22 [1.69, 2.75] g/dL after Ferinject and 1.92 [1.43, 2.41] g/dL after oral iron sulphate. In total, 87.5% of patients in the intravenous iron group achieved a Hb increase >1 g/dL at EOS. The increase in ferritin and TSAT, used as a measure for the replenishment of iron stores, was higher after Ferinject therapy compared to oral iron sulphate therapy, with an increase in ferritin from baseline to day 35 (LS Mean [95%CI]) of 132.1 [105.44, 158.76] ng/mL after Ferinject and 11.0 [-15.62, 37.65] ng/mL after oral iron sulphate. The corresponding increase in TSAT was 24.3 [19.19, 29.41] % and 8.7 [3.70, 13.63] %, respectively. See also section 4.8.

Ferritin monitoring after replacement therapy

There is limited data from study VIT-IV-CL-008 which demonstrates that ferritin levels decrease rapidly 2– 4 weeks following replacement and more slowly thereafter. The mean ferritin levels did not drop to levels where retreatment might be considered during the 12 weeks of study follow up. Thus, the available data does not clearly indicate an optimal time for ferritin retesting although assessing ferritin levels earlier than 4 weeks after replacement therapy appears premature. Thus, it is recommended that further re-assessment of ferritin should be made by the clinician based on the individual patient’s condition.

5.2 Pharmacokinetic properties

Distribution

Positron emission tomography demonstrated that 59 Fe and 52 Fe from Ferinject was rapidly eliminated from the blood, transferred to the bone marrow, and deposited in the liver and spleen.

After administration of a single dose of Ferinject of 100 to 1,000 mg of iron in ID subjects, maximum total serum iron levels of 37 µ g/mL up to 333 µ g/mL are obtained after 15 minutes to 1.21 hours, respectively. The volume of the central compartment corresponds well to the volume of the plasma (approximately 3 litres).

Elimination

The iron injected or infused was rapidly cleared from the plasma, the terminal half-life ranged from 7 to 12 hours, the mean residence time (MRT) from 11 to 18 hours. Renal elimination of iron was negligible.

Paediatric population

The pharmacokinetic properties of Ferinject at a dose of 15 mg iron/kg were similar to those for adult patients with iron deficiency. Serum iron increased proportionally to the dose after a single dose of 7.5 mg iron/kg or 15 mg iron/kg. After a single dose of Ferinject of 15 mg iron/kg body weight (maximum 750 mg), average maximum total serum iron values of 310 µ g/mL were measured after 1.12 hours. The terminal half-life was 9.8 hours, and the distribution volume estimated by the population pharmacokinetic analysis was 0.42 to 3.14 l. Based on model-based simulations, the paediatrics subjects tended to have lower systemic exposure (lower AUC_0-72h) compared to the adults (median per age group: 3,340 μ g× h/mL (1 to 2 years), 4,110 μ g× h/mL (3 to 12 years), 4,740 μ g× h/mL (13 to 17 years), 8,864 μ g× h/mL (adults)).

5.3 Preclinical safety data

Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeat dose toxicity and genotoxicity. Preclinical studies indicate that iron released from Ferinject does cross the placental barrier and is excreted in milk in limited, controlled amounts. In reproductive toxicology studies using iron replete rabbits Ferinject was associated with minor skeletal abnormalities in the fetus. In a fertility study in rats, there were no effects on fertility for either male or female animals. No long-term studies in animals have been performed to evaluate the carcinogenic potential of Ferinject. No evidence of allergic or immunotoxic potential has been observed. A controlled in-vivo test demonstrated no cross-reactivity of Ferinject with anti-dextran antibodies. No local irritation or intolerance was observed after intravenous administration.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium hydroxide (for pH adjustment)

Hydrochloric acid (for pH adjustment)

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

The compatibility with containers other than polypropylene, polyethylene and glass is not known.

6.3 Shelf life

Shelf life of the product as packaged for sale:

Shelf life after first opening of the container:

From a microbiological point of view, preparations for parenteral administration should be used immediately.

If not used immediately, in-use storage times and conditions are the responsibility of the user. Administration of the product must be carried out under controlled and validated aseptic conditions.

Chemical and physical in-use stability has been demonstrated for 7 days at 30° C.

Shelf life in polyethylene and polypropylene containers after dilution with sterile 0.9% m/V sodium chloride solution:

From a microbiological point of view, preparations for parenteral administration should be used immediately after dilution with sterile 0.9% m/V sodium chloride solution.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8° C.

Chemical and physical in-use stability has been demonstrated for 72 hours at 30° C at concentrations of 2 mg/ml and 5 mg/ml.

Shelf life in polypropylene syringe (undiluted):

From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8° C.

Chemical and physical in-use stability has been demonstrated for 72 hours at 30° C.

6.4 Special precautions for storage

Store in the original package in order to protect from light. Do not store above 30 ° C. Do not freeze.

For storage conditions after dilution or first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Ferinject is supplied in a vial (type I glass) with a stopper (bromobutyl rubber) and an aluminium cap containing:

– 2 mL dispersion. Pack sizes of 1, 2 or 5 vials.

– 10 mL dispersion. Pack sizes of 1, 2 or 5 vials.

– 20 mL dispersion. Pack size of 1 vial.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Inspect vials visually for sediment and damage before use. Use only those containing sediment-free, homogeneous dispersion.

For storage conditions after dilution or first opening of the medicinal product, see section 6.3.

Each vial of Ferinject is intended for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.

Ferinject must only be mixed with sterile 0.9% m/V sodium chloride solution. No other intravenous dilution solutions and therapeutic agents should be used, as there is the potential for precipitation and/or interaction. For dilution instructions, see section 4.2.

7. Marketing authorisation holder

100– 101 Terrasse Boieldieu

Tour Franklin La Dé fense 8

92042 Paris La Dé fense Cedex

Tel. +33 (0)1 41 06 58 90

Fax +33 (0)1 41 06 58 99

8. Marketing authorisation number(s)
9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 19.07.2007

Date of latest renewal: 18.06.2012

Условия отпуска из аптек

В защищенном от света месте, при температуре не выше 25 °C.
Хранить в недоступном для детей месте.
3 года.
Не применять по истечении срока годности, указанного на упаковке.

Крылов Юрий Федорович (фармаколог, доктор медицинских наук, профессор, академик Международной академии информатизации)
Опыт работы: более 33 лет

Дата обновления: 18.03.2024

Аналоги (синонимы) препарата АЦЦ ® инъект

Реклама: ИП Вышковский Евгений Геннадьевич, ИНН 770406387105

Реклама: ИП Вышковский Евгений Геннадьевич, ИНН 770406387105

Реклама: Общероссийская общественная организация «Российское научное медицинское общество терапевтов», ИНН 7702370661

Реклама: ООО «ЕВРОЭКСПО», ИНН 7729429827

Реклама: ООО «МЕДИ Экспо», ИНН 7728812900

Реклама: ООО «МЕДиКОН», ИНН 6732026657

Информация исключительно для работников здравоохранения.
Являетесь ли Вы специалистом здравоохранения?

Да Нет

Материалы сайта предназначены исключительно для медицинских и фармацевтических работников, носят справочно-информационный характер и не должны использоваться пациентами для принятия самостоятельного решения о применении лекарственных средств.

Официальный сайт системы справочников РЛС ® — энциклопедия лекарств и товаров аптечного ассортимента. Справочник лекарственных препаратов Rlsnet.ru предоставляет пользователям доступ к инструкциям, ценам и описаниям лекарственных средств, БАДов, медицинских изделий, медицинских приборов и других товаров. Фармакологический справочник включает информацию о составе и форме выпуска, фармакологическом действии, показаниях к применению, противопоказаниях, побочных действиях, взаимодействии лекарств, способе применения лекарственных препаратов, фармацевтических компаниях. Лекарственный справочник содержит цены на лекарства и товары фармацевтического рынка в Москве и других городах России.

Запрещена передача, копирование, распространение информации без разрешения администратора сайта, а также коммерческое использование материалов. При цитировании информационных материалов, опубликованных на страницах сайта www.rlsnet.ru, ссылка на источник информации обязательна.

Сетевое издание «Регистр лекарственных средств России РЛС» (доменное имя сайта: rlsnet.ru) зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор), регистрационный номер и дата принятия решения о регистрации: серия Эл № ФС77-85156 от 25 апреля 2023 г.

Инжектор Extreme Injector

Extreme Injector by master131 мощный, но в тоже время простой инжектор dll-ок. Необходим для инжекта dll-читов для многих игр.

• Лист процессов с удобными фильтрами
• Поддержка перетаскивания мышкой
• Поддержка 64-битных систем
• Multi-DLL injection — инжект в один процесс несколько dll
• Auto-Inject
• Stealth Inject
• Close on inject — инжект сразу после закрытия определенного процесса
• DLL Scrambling — делает dll файлы гораздо более незаметными для защиты
• Различные способы инжекта (Standard, LdrLoadDll Stub, Thread Hijacking and Manual Map)

How does it compare?

The efficacy of FCM for correcting IDA has been evaluated across a range of clinical conditions including IBD, 14 , 15 , CKD, 16 , 17 chronic heart failure, 18 menorrhagia 19 and postpartum anaemia. 20-22

Haemoglobin response similar to that with iron sucrose, but with fewer doses

Results from prospective and retrospective trials have confirmed that large doses of FCM given in fewer injections can increase Hb levels with efficacy comparable to that of multiple small dose injections of iron sucrose. 15 , 23-25

In the 8-week REPAIR-IDA trial, 23 involving IDA patients with non-dialysis-dependent CKD, two doses of FCM (750 mg/dose, n = 1276) were shown to be non-inferior to a typical dosing strategy of iron sucrose (five or fewer infusions of 200 mg, n = 1285).

More people treated with FCM had a sustained Hb increase of ≥ 10 g/L from baseline to study end than for those given iron sucrose (48.6% vs 41.0%, 95% CI 3.6% to 11.6%). 23

Mean increases in serum ferritin and transferrin saturation were also significantly greater in the FCM group compared with the iron sucrose group. The mean total iron dose received over the treatment phase was 1464 ± 158 mg in the FCM group and 963 ± 138 mg in the iron sucrose group. 23

Similarly, among patients with IDA and associated IBD, three or fewer 500–1000 mg FCM infusions showed improved efficacy compared with iron sucrose (up to 11 infusions of 200 mg iron) in the 12-week FERGIcor trial. 15

A small difference in mean total dose was reported for these treatment groups; 1377 ± 381 mg (FCM) and 1160 ± 316 mg (iron sucrose). 15

At the end of the study, 66% of the FCM cohort had experienced a ≥ 20 g/L Hb increase compared with 54% of the iron sucrose arm (p = 0.004). 15

More people in the FCM treatment group experienced correction of anaemia compared with the iron sucrose group at study end (73% vs 62%, respectively, p = 0.015). 15

The simpler FCM dosing regimen was also associated with greater patient compliance compared with iron sucrose (p < 0.001). 15

Improves anaemia as well as, or better than, oral iron and standard medical care

The efficacy of FCM for the treatment of iron-deficiency anaemia was compared with oral iron (ferrous sulphate) in several randomised open-label trials. 14 , 16 , 19-22

Overall, FCM (≤ 1000 mg per infusion) was at least as effective, 14 , 20 , 21 or more effective, 16 , 19 , 22 , 26 than oral iron (ferrous sulphate 325 mg three times daily or 100 mg twice daily) at correcting haemoglobin, ferritin and transferrin saturation levels. Perhaps not surprisingly, haemoglobin increases were more rapid with FCM than with oral iron therapy. 19 , 22

The comparative effectiveness of FCM in treating iron-deficiency anaemia versus standard medical care (including IV iron formulations) has also been investigated in several randomised controlled trials. 17 , 26-28

Clinically meaningful improvements in haemoglobin and iron indices have been observed compared with standard medical care in patients with IDA associated with conditions such as CKD, menorrhagia, IBD and after post-bariatric surgery or delivery. 17 , 26-28

Clinical equivalence with IV iron polymaltose is not known

To date, there have been no head-to-head comparisons of FCM with iron polymaltose, which is FDM’s main IV iron formulation comparator in Australia. 1

Indirect comparisons between FCM and iron polymaltose, based on their efficacy relative to oral iron, are also not possible due to marked heterogeneity in patients and outcomes.

Инжект

Такой страницы не существует

Воспользуйтесь поиском или посмотрите другие материалы

Статьи 2 октября Что такое омологация шин и для чего она нужна

Статьи 1 октября Как подорожал бензин в России за 10 лет. Цены тогда и сейчас

Статьи 1 октября Утильсбор на машины в России вырос на 80%: чем это грозит автомобилистам

Статьи 1 октября Что изменится для водителей с 1 октября: цены, штрафы и страховка

Социальные сети

Подписки

Юридическая Информация

© АО «РОСБИЗНЕСКОНСАЛТИНГ», 1995–2024. 18+ [email protected] Котировки мировых финансовых инструментов предоставлены Reuters Материалы с отметкой «Новости компаний» публикуются на правах рекламы Чтобы отправить редакции сообщение, выделите часть текста в статье и нажмите Ctrl+Enter

Источники:

https://polimerinjekt.com/&rut=e65c5db57ec520f8b69b17829f45fceb1c999340ebf4bd9869922668b2cde312
https://injekt.ru/&rut=e436b4e1a3c1a8209e8e47c4ab4c9b459c92a708e6d1149abd8567625f4d588e
https://www.medicines.org.uk/emc/product/5910/smpc&rut=175b6a97bb5a2e6ba013a098a31bcadc445a590498526c50e0c305572fd82fac
https://www.rlsnet.ru/drugs/acc-inekt-3708&rut=e027731cfd9d94fd1822884613359c182709007b7bdee59048fab9ea46fcd940
https://ezcheats.ru/tools/inzhektor-extreme-injector-v33.html&rut=cae8b583190c316a296e081dadfe7f6f53d730e5302cf5bf31c22cfce525e23e
https://www.nps.org.au/radar/articles/ferric-carboxymaltose-ferinject-for-iron-deficiency-anaemia&rut=f8b724bb973ee1049baef2df9a55e161b1639057b1d4fc98ab702db9dc75fbe1
https://www.autonews.ru/news/65794d1e9a79471dfd7b19d9&rut=a11967bb39fb8ff801cb663e22e27326c9df47966c263b0ae2c43fd28f8ebcdb